Pediatric Hepatic Tumors
NCT04274868 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2020-02-18
Summary
Centralized biological collection of multicentric origin, retrospective and prospective of biological samples (tissues and fluids) taken within the framework of the diagnostic and therapeutic management of children and adolescents with liver tumor, and supported in the centers of French Society for Childhood Cancers (SFCE) with associated clinical database.
Conditions
- Liver Tumor
Sponsors & Collaborators
-
Gustave Roussy, Cancer Campus, Grand Paris
lead OTHER
Eligibility
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-09-10
- Primary Completion
- 2025-09-30
- Completion
- 2025-09-30
Countries
- France
Study Locations
More Related Trials
-
Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience
NCT02557750 ·Status: UNKNOWN
-
Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma
NCT04340986 ·Status: RECRUITING
-
TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma
NCT05555316 ·Status: UNKNOWN ·Phase: PHASE2
-
TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma
NCT02704130 ·Status: TERMINATED ·Phase: NA
-
The Overall Survival of Patients With Unresectable HCC in Real-life
NCT03612726 ·Status: RECRUITING
-
Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients
NCT05213221 ·Status: COMPLETED ·Phase: PHASE2
-
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
NCT05842317 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
NCT04560751 ·Status: UNKNOWN
-
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
NCT07131501 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Liver Resection Versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma
NCT02232932 ·Status: UNKNOWN ·Phase: NA
-
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
NCT04634357 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Primary Hepatobiliary Cancer Cohort of Central China
NCT05520801 ·Status: RECRUITING
-
Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB
NCT07160361 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Efficacy of Radiation Therapy and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma (HCC)
NCT01432314 ·Status: WITHDRAWN ·Phase: PHASE2
-
Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma
NCT00667628 ·Status: TERMINATED ·Phase: PHASE2
-
Combined Therapy for Hepatocellular Carcinoma >3-<5 cm
NCT04721470 ·Status: COMPLETED ·Phase: NA
-
Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis
NCT01079767 ·Status: TERMINATED ·Phase: PHASE2
-
Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma
NCT04993131 ·Status: RECRUITING ·Phase: NA
-
Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma
NCT03748927 ·Status: WITHDRAWN
-
Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC
NCT04911959 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma
NCT02646137 ·Status: UNKNOWN ·Phase: PHASE3
-
FibroLamellar Carcinoma: an International Registry Study
NCT05730686 ·Status: UNKNOWN
-
Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC
NCT02254681 ·Status: TERMINATED ·Phase: PHASE2
-
Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma
NCT02755311 ·Status: UNKNOWN ·Phase: PHASE3
-
The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study
NCT04909866 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3